Gilad Mamlok - 24 Aug 2025 Form 3/A - Amendment Insider Report for Protalix BioTherapeutics, Inc. (PLX)

Reporting relationship: Sr. VP and CFO
Issuer ticker: PLX
Reported as of: 24 Aug 2025
Net transaction value: $0
SEC form: 3/A - Amendment
Accepted by SEC: 27 Apr 2026, 17:00:21 UTC
Original report date: 25 Aug 2025
Next SEC filing: 18 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Gilad Mamlok

Key filing fact

Gilad Mamlok filed Form 3/A - Amendment for Protalix BioTherapeutics, Inc. (PLX) on 27 Apr 2026.

Key facts

This page summarizes Gilad Mamlok's Form 3/A - Amendment filing for Protalix BioTherapeutics, Inc. (PLX).
0 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 27 Apr 2026, 17:00.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3/A - Amendment disclosures.

View source filing

Reporting Owners (1)

CIK 0001975896 Primary reporting owner

Mamlok Gilad

Relationship: Sr. VP and CFO
Address: CO PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT STREET, SCIENCE PARK, P.O. BOX, CARMIEL, ISRAEL
Signature: /s/ Gilad Mamlok
Signature date: 27 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PLX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 3,631
Date: 24 Aug 2025
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PLX holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 24 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 597,990
Exercise price: $1.45
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended.

SEC remarks

On August 25, 2025, the reporting person filed a Form 3 which inadvertently omitted the reporting person's beneficial ownership of 3,631 shares of the issuer's common stock.